标题
Ixazomib for the treatment of multiple myeloma
作者
关键词
-
出版物
EXPERT OPINION ON PHARMACOTHERAPY
Volume 19, Issue 17, Pages 1949-1968
出版商
Informa UK Limited
发表日期
2018-11-14
DOI
10.1080/14656566.2018.1528229
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma
- (2018) Xavier Leleu et al. AMERICAN JOURNAL OF HEMATOLOGY
- Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma
- (2018) Paul G. Richardson et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma
- (2018) Jesús F. San-Miguel et al. HAEMATOLOGICA
- NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018
- (2018) Shaji K. Kumar et al. Journal of the National Comprehensive Cancer Network
- The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed/refractory multiple myeloma in the era of novel therapies
- (2018) Parameswaran Hari et al. Journal of Geriatric Oncology
- A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma
- (2018) Jesús F. San-Miguel et al. HAEMATOLOGICA
- Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs . placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1
- (2017) María-Victoria Mateos et al. HAEMATOLOGICA
- Maintenance Lenalidomide After Transplantation in Multiple Myeloma Prolongs Survival—In Most
- (2017) Joseph R. Mikhael JOURNAL OF CLINICAL ONCOLOGY
- Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study
- (2017) Jian Hou et al. Journal of Hematology & Oncology
- Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial
- (2017) Brian G M Durie et al. LANCET
- Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma
- (2017) A Krishnan et al. LEUKEMIA
- RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma
- (2017) E Viziteu et al. LEUKEMIA
- Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses
- (2017) Neeraj Gupta et al. Targeted Oncology
- Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma
- (2017) N Tandon et al. Blood Cancer Journal
- A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma
- (2017) A K Mitra et al. Blood Cancer Journal
- Emerging drugs and combinations to treat multiple myeloma
- (2017) Alessandra Larocca et al. Oncotarget
- Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs . placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1
- (2017) María-Victoria Mateos et al. HAEMATOLOGICA
- Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial
- (2017) Sarah A Holstein et al. Lancet Haematology
- Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials
- (2016) Maria-Victoria Mateos et al. ANNALS OF HEMATOLOGY
- Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma
- (2016) H. Avet-Loiseau et al. BLOOD
- Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib
- (2016) S. K. Kumar et al. BLOOD
- Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
- (2016) P. Sonneveld et al. BLOOD
- The effects of proteasome inhibitors on bone remodeling in multiple myeloma
- (2016) Maurizio Zangari et al. BONE
- Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment
- (2016) Neeraj Gupta et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Multiple myeloma: practice patterns across Europe
- (2016) Marc S. Raab et al. BRITISH JOURNAL OF HAEMATOLOGY
- A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis
- (2016) Neeraj Gupta et al. BRITISH JOURNAL OF HAEMATOLOGY
- International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
- (2016) Meletios A. Dimopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
- (2016) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Trends in overall survival and costs of multiple myeloma, 2000–2014
- (2016) R Fonseca et al. LEUKEMIA
- Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma
- (2016) Kevin Barley et al. LEUKEMIA & LYMPHOMA
- A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation
- (2016) Katja Weisel et al. LEUKEMIA & LYMPHOMA
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Philippe Moreau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices
- (2016) Sundar Jagannath et al. Expert Review of Hematology
- Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial
- (2016) J R Jones et al. Blood Cancer Journal
- The role of maintenance therapy in multiple myeloma
- (2016) B Lipe et al. Blood Cancer Journal
- Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study
- (2015) María Victoria Mateos et al. AMERICAN JOURNAL OF HEMATOLOGY
- Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
- (2015) A. Palumbo et al. BLOOD
- Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis
- (2015) Neeraj Gupta et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Molecular basis of resistance to proteasome inhibitors in hematological malignancies
- (2015) Denise Niewerth et al. DRUG RESISTANCE UPDATES
- Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies
- (2015) David C. Smith et al. INVESTIGATIONAL NEW DRUGS
- Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma
- (2015) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
- (2015) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacokinetics and safety of ixazomib plus lenalidomide–dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study
- (2015) Neeraj Gupta et al. Journal of Hematology & Oncology
- Multiple myeloma
- (2015) Christoph Röllig et al. LANCET
- Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group
- (2015) J Laubach et al. LEUKEMIA
- When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response
- (2015) S. P. Shah et al. MOLECULAR CANCER RESEARCH
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life
- (2015) R. Baz et al. SUPPORTIVE CARE IN CANCER
- Optimizing quality of life in multiple myeloma patients: current options, challenges and recommendations
- (2015) Helena Maes et al. Expert Review of Hematology
- Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
- (2015) S K Kumar et al. Blood Cancer Journal
- Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling
- (2015) Fabrizio Accardi et al. Biomed Research International
- Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma
- (2014) J. Martinez-Lopez et al. BLOOD
- Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma
- (2014) S. K. Kumar et al. BLOOD
- Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients
- (2014) P. G. Richardson et al. BLOOD
- Understanding what matters most to people with multiple myeloma: a qualitative study of views on quality of life
- (2014) Thomas R Osborne et al. BMC CANCER
- Preclinical Activity of the Oral Proteasome Inhibitor MLN9708 in Myeloma Bone Disease
- (2014) A. Garcia-Gomez et al. CLINICAL CANCER RESEARCH
- Maintenance therapy in newly diagnosed multiple myeloma: current recommendations
- (2014) Annamaria Brioli et al. Expert Review of Anticancer Therapy
- Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study
- (2014) Shaji K Kumar et al. LANCET ONCOLOGY
- Improved long-term survival in multiple myeloma up to the age of 80 years
- (2014) S Y Kristinsson et al. LEUKEMIA
- Current treatment landscape for relapsed and/or refractory multiple myeloma
- (2014) Meletios A. Dimopoulos et al. Nature Reviews Clinical Oncology
- Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
- (2014) Lotfi Benboubker et al. NEW ENGLAND JOURNAL OF MEDICINE
- An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma
- (2014) Massimo Offidani et al. OncoTargets and Therapy
- Current strategies for treatment of relapsed/refractory multiple myeloma
- (2014) Jacob P Laubach et al. Expert Review of Hematology
- Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma
- (2014) S E Assouline et al. Blood Cancer Journal
- Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results
- (2013) F. Gay et al. BLOOD
- Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis
- (2013) Samantha Pozzi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma
- (2013) Chungyee Leung-Hagesteijn et al. CANCER CELL
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
- (2013) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- Minimal Residual Disease in Multiple Myeloma
- (2013) Nikhil C. Munshi et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials
- (2013) Pieter Sonneveld et al. JOURNAL OF CLINICAL ONCOLOGY
- Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
- (2013) S K Kumar et al. LEUKEMIA
- Review of health-related quality of life data in multiple myeloma patients treated with novel agents
- (2013) P Sonneveld et al. LEUKEMIA
- Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013
- (2013) Joseph R. Mikhael et al. MAYO CLINIC PROCEEDINGS
- Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial
- (2012) M.-V. Mateos et al. BLOOD
- IMWG consensus on maintenance therapy in multiple myeloma
- (2012) H. Ludwig et al. BLOOD
- Proteasome inhibitors in multiple myeloma: 10 years later
- (2012) P. Moreau et al. BLOOD
- Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma
- (2012) P. L. Bergsagel et al. BLOOD
- Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial
- (2012) Pieter Sonneveld et al. JOURNAL OF CLINICAL ONCOLOGY
- Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
- (2012) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p
- (2011) K. Neben et al. BLOOD
- Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma
- (2011) P. Moreau et al. BLOOD
- Responsiveness and minimal important score differences in quality-of-life questionnaires: a comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma
- (2011) Ann Kristin Kvam et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1
- (2011) S. C. W. Ling et al. HAEMATOLOGICA
- Management of treatment-emergent peripheral neuropathy in multiple myeloma
- (2011) P G Richardson et al. LEUKEMIA
- Multiple Myeloma
- (2011) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improvement in Survival of Older Adults with Multiple Myeloma: Results of an Updated Period Analysis of SEER Data
- (2011) D. Pulte et al. ONCOLOGIST
- Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
- (2010) E. Kupperman et al. CANCER RESEARCH
- Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial
- (2010) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
- (2010) Michele Cavo et al. LANCET
- Health-related quality of life assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations
- (2009) Ann Kristin Kvam et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Patterns of Improved Survival in Patients With Multiple Myeloma in the Twenty-First Century: A Population-Based Study
- (2009) Ingemar Turesson et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
- (2008) Jesús F. San Miguel et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started